Affiliation:
1. Department of Pharmacy University of Washington Seattle WA USA
2. School of Medicine University of California San Francisco San Francisco CA USA
3. Seattle Children's Hospital Seattle WA USA
4. Department of Pediatrics University of Washington Seattle WA USA
Abstract
Adolescent transgender medicine is a growing clinical field. Gender‐affirming medications for transgender youth may include gonadotropin‐releasing hormone (GnRH) agonists, gender‐affirming hormones or both. To evaluate the potential effects of GnRH agonists (puberty suppression) on pharmacokinetic processes for transgender youth, we searched PubMed from inception to May 2024 for publications on the effects of GnRH agonists on drug absorption, distribution, metabolism or excretion for transgender adolescents or effects on hormones (including gonadotropins, adrenal androgens, sex steroids) that are associated with changes in drug metabolism during puberty in the general adolescent population. No publications discussed the effects of GnRH agonist treatment on pharmacokinetic processes for adolescent transgender people. Sixteen publications observed marked decreases in gonadotropins and sex steroids for both adolescent transgender men and adolescent transgender women and slight effects on adrenal androgens. During GnRH agonist treatment, changes in body composition and body shape were greater for adolescent transgender people than for cisgender adolescent people. Further research is needed to better understand the effects of GnRH agonists on drug metabolism and other pharmacokinetic processes for transgender adolescents receiving GnRH agonists and other gender‐affirming medications.
Funder
National Institute of General Medical Sciences
National Institutes of Health
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Moving forward to ‘put people first’;British Journal of Clinical Pharmacology;2024-06